Abstract
Background:
Clofazimine inhalation suspension is a novel formulation of clofazimine developed as a potential lung-targeted treatment for pulmonary nontuberculous mycobacteria disease.
Methods:
Safety and toxicokinetic parameters were assessed in 28-day, repeat-dose studies of up to 3.59 mg/kg/day clofazimine inhalation suspension in 8-week-old Sprague Dawley rats and up to 2.72 mg/kg/day in 5–7-month-old beagle dogs with 56-day recovery periods. A 6-month inhalation toxicity study without recovery was also conducted in beagle dogs, with daily doses up to 2.95 mg/kg for 182 days.
Results:
No adverse effects were observed, but minimal to mild nonadverse pulmonary changes were observed in high-dose treatment groups. The no-observed-adverse-effect levels were a sex-averaged 1.78 mg/kg in rats (28 days) and 2.73/2.95 mg/kg in male/female dogs (182 days). Median time to maximum concentration ranged from 6 to 12 hours and 0.5 to 6 hours in the rat and dog studies, respectively. Plasma area under the concentration–time curve from 0 to 24 hours and maximum plasma concentration increased dose-dependently and exhibited accumulation ratios ≥∼2 in both 28-day studies. Clofazimine concentrations in lung tissue were dose-dependent in all 3.
Discussion:
Clofazimine inhalation suspension was well tolerated at doses supporting multifold safety margins for the ongoing phase 3 ICoN-1 study. Lung concentrations exceeded the estimated minimum inhibitory concentration against Mycobacterium avium complex, even after 56 days of recovery.
Get full access to this article
View all access options for this article.